Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Chemotherapy after surgery extends survival for patients with advanced endometrial cancer

07.12.2005


A new study has shown for the first time that giving two chemotherapy drugs to women with advanced endometrial cancer after surgery reduced the risk of recurrence by 29% and extended survival by 32% compared with women who received whole abdominal irradiation. The findings could improve the care for the 15% to 20% of patients with endometrial cancer who have advanced disease. The study will be published online December 5 in the Journal of Clinical Oncology (JCO).



Endometrial cancer is the most common gynecologic cancer in the United States – the American Cancer Society estimates that in 2005, 40,880 women will be diagnosed with the disease, and 7,310 will die.

"For the first time, adjuvant chemotherapy has been shown to extend survival in patients with advanced endometrial cancer," said the study’s lead author, Marcus E. Randall, MD, Director of the Leo W. Jenkins Cancer Center at the Brody School of Medicine at East Carolina University in Greenville, North Carolina. "These findings were surprising, given that previous studies showed that single chemotherapy agents do not have a significant impact on the disease."


Researchers from the Gynecologic Oncology Group (GOG) compared the rate of recurrence and overall survival between 194 women with advanced endometrial cancer who received chemotherapy with the drugs doxorubicin and cisplatin over a period of five months and 202 women who received radiation therapy to the entire abdomen over a period of approximately 1.5 months. Patients were enrolled in the trial from 1992 until 2001. Researchers followed patients for a median of just over six years, and used a statistical model to estimate five-year recurrence and survival rates.

After five years, 50% of patients who received chemotherapy were estimated to be free of disease compared with 38% of those who received whole abdominal irradiation. Moreover, 55% of patients who received chemotherapy were estimated to be alive after five years, compared with 42% of patients in the radiation therapy group.

However, serious adverse side effects were more common in the chemotherapy group. The most common serious side effects included reduced blood cell counts and problems with the digestive and nervous systems, liver, and heart. Treatment-related deaths were also twice as common in the chemotherapy group (4%, vs. 2% of radiation patients).

Another GOG study is underway to see if the chemotherapy drugs carboplatin and paclitaxel will be as effective, but with fewer serious side effects. A less toxic regimen could help a greater number of patients with advanced disease, many of whom are elderly or have other illnesses that might prohibit the use of the aggressive chemotherapy regimen.

In addition, another GOG study evaluated the use of combination chemotherapy after "involved field" radiation therapy (radiation to less than the whole abodomen) to see if these patients might benefit more than those who receive either treatment alone. Results from this study are not yet available.

"This study represents a major advance in the treatment of advanced endometrial cancer," noted Gini F. Fleming, MD, Director of the Medical Oncology Gynecologic and Breast Cancer Programs at the University of Chicago, and author of an accompanying editorial. "Future trials need to address treatment of earlier-stage disease, optimization of chemotherapy regimen, integration of radiotherapy, and application of newer targeted agents."

Danielle Potuto | EurekAlert!
Further information:
http://www.asco.org

More articles from Studies and Analyses:

nachricht Win-win strategies for climate and food security
02.10.2017 | International Institute for Applied Systems Analysis (IIASA)

nachricht The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>